Hotgen Biotech (688068.SH) subsidiary SGC001 innovative drug "expected severe acute pancreatitis" indication Phase II clinical study completes first subject enrollment and dosing

Zhitong Finance APP News: Hotgen Biotech (688068.SH) announced that recently, the Phase II clinical study of the innovative drug SGC001 Injection, independently developed by its controlling subsidiary Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (referred to as "Shunjing Pharma"), for the "expected severe acute pancreatitis" indication has completed the first subject enrollment and dosing.